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Fibrinolysis and beyond: bridging the gap between local  
and systemic clot removal
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Recanalization methods in ischemic stroke have been progressively expanded over the past years. 
In addition the continuous development of specialized mechanical devices for thrombectomy 
a broad spectrum of new drugs has been tested: Both options, novel drugs as well as new 
devices, can be employed independently of each other, but in most cases a combination of the 
two with the standard treatment of intravenous fibrinolysis is applied. Until recently, a large 
number of case series have been performed to investigate the effects of various drugs and 
interventions, but only a few trials have been conducted to determine the optimal conditions 
for combining both procedures. This review surveys the different systemic and endovascular 
vessel reopening practices and their major bridging techniques.
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processing IAT and/or mechanical intra-arterial  procedures. Yet 
despite a considerable number of different techniques the opti-
mal crossover between intravenous and intra-arterial measures 
is still unavailable. Here we summarize the current data for the 
major recanalization-techniques and the various options for 
combining them. Finally, we propose a protocol for an actual 
bridging practice.
Intravenous thrombolysIs
Intravenous recombInant tIssue-type plasmInogen 
actIvator
After a number of studies involving intravenous application of 
streptokinase attempted to resolve the therapeutic nihilism in 
ischemic stroke (MAST-I, 1995; Donnan et al., 1996; MAST-E, 
1996), the NINDS-study group, in 1995, published their landmark-
findings from a study of 624 patients with acute ischemic stroke 
(National Institute of Neurological Disorders, and Stroke rt-PA 
Stroke Study Group, 1995). In this study patients received 0.9 mg/
kg/body weight (BW) of alteplase within 3 h of symptom onset. 
Patients in the treatment group were at least 30% more likely to 
have minimal or no disability at 3 months than those who received 
a placebo.
By comparison, two European trials: the European Cooperative 
Acute Stroke Study I (ECASS I) and ECASS II, investigated a time 
window of up to 6 h but failed to show the efficacy of thrombo-
lytic treatment, as defined by each trial (Hacke et al., 1995, 1998). 
Nevertheless, the results from an extensive review (Wardlaw et al., 
2003) of 18 fibrinolytic trials suggested a positive effect for rtPA 
given up to 6 h. Furthermore, a pooled analysis of the common data 
elements from six randomized placebo-controlled trials, including 
ATLANTIS (Part A and B), ECASS (both trials), and NINDS (Part 
1 and 2) which investigated thrombolysis with rtPA for ischemic 
stroke, reported favorable outcomes even when therapy was 
administered between 3.0 and 4.5 h after symptom onset (Hacke 
et al., 2004). In 2008, the ECASS-3 trial confirmed this finding 
(Hacke et al., 2008).
background and purpose
Reperfusion is the primary therapeutic goal during acute ischemic 
stroke. By restoring blood flow to the affected vessel, reperfusion 
therapies save penumbral tissue, reduce final infarct size and 
result in an improved clinical outcome. The standard reperfusion 
method – intravenous recombinant tissue-type plasminogen 
activator (I.V.-rtPA) is the quickest way to initiate thrombolysis 
for acute ischemic stroke. At present treatment is recommended 
within the first 3 h after symptom onset, but the time window can 
be extended to 4.5 h based on the increasing evidence of benefit in 
patients treated within this interval (Hacke et al., 2008; Wahlgren 
et al., 2008). The effect of fibrinolysis depends chiefly on reca-
nalization, which increases the probability of a favorable clinical 
outcome by a four- to fivefold factor. Intravenous fibrinolysis 
however reopens an occluded vessel in less than half of all cases 
(Rha et al., 2007). Moreover it recanalizes only one out of three 
patients with an occlusion of the proximal middle cerebral artery 
and only about one out of 10 patients in cases of thrombosis 
of the internal carotid artery (ICA; Mori et al., 1992; Wolpert 
et al., 1993; Tomsick et al., 1996; IMS Study Investigators, 2004). 
Therefore, particularly the prognosis of patients with clinically 
severe ischemic strokes caused by occlusions in the proximal 
vascular bed remains relatively poor. In these cases endovascu-
lar methods clearly provide higher recanalization rates at the 
expense of a longer delay in treatment initiation. The time to 
recanalization however is in itself a very substantial predictor 
of clinical outcome (Ringelstein et al., 1992; Heiss et al., 1998; 
Christou et al., 2000). Thus procedures such as intra-arterial 
thrombolysis (IAT) and mechanical thrombectomy improve 
recanalization rates considerably, but there is substantial doubt 
with regard to the ultimate superiority of their clinical efficacy. To 
avoid low recanalization rates by I.V.-rtPA or delayed reopening 
by IAT a bridging approach of both methods is more auspicious 
than one single method in isolation. The combination of both 
methods provides the advantages of early treatment initiation via 
I.V.-rtPA as well as higher recanalization rates by subsequently 
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escalation of desmoteplase for acute ischemic stroke trial (DEDAS), 
based on the same study protocol as the previous study, corrobo-
rated these findings (Furlan et al., 2006). However the consecutive 
follow-up trial DIAS II (Hacke et al., 2009) did not confirm the 
benefit by DSPA. It has been speculated that this was attributable 
to an uncommon spontaneous reopening rate of 50% in the pla-
cebo group, but the exact reasons for the discordant result are still 
unknown. Meanwhile a third DIAS-trial is on the way.
Similar to DSPA, ancrod, a substance which induces rapid 
defibrinogenation in humans by splitting fibrinopeptide A from 
fibrinogen, is derived from a non-human source. The purified frac-
tion of the venom of the Malaysian spit viper has been investigated 
in acute ischemic stroke and has produced favorable outcomes in 
an initial randomized, placebo-controlled study (Sherman et al., 
2000), in which 500 patients with an acute ischemic stroke were 
treated with ancrod versus a placebo. However several consecutive 
trials, in which ancrod was administered within a 3- or 6-h window, 
revealed inconsistent results. Finally Levy et al. (2009) failed to 
show an improvement in outcome in 500 randomized patients in 
the ASP-study, even after adjusting the timing and dosage regimes 
to the experiences of the preceding studies, and there was also still 
a trend to increased bleeding rates.
glycoproteIn IIb/IIIa antagonIsts – abcIxImab, tIrofIban, and 
eptIfIbatIde
The glycoprotein (GP) IIb/IIIa complex is the major integrin 
present on the platelet surface and plays a key role in platelet 
aggregation. The use of GP-IIb/IIIa antagonists is widespread and 
very common for cardiological purposes because of its efficacy in 
coronary interventions (Cura et al., 2000). Whereas Eptifibatide 
and Tirofiban as separate treatment options for ischemic stroke 
have only been investigated in retrospective case series (Martin-
Schild et al., 2009) or in case reports (Liebeskind et al., 2002), 
Abciximab, the recombinant Fab fragment of a monoclonal anti-
GP-IIb/IIIa antibody has been investigated more extensively. After 
encouraging Phase I and II trials (Abciximab in Ischemic Stroke 
Investigators, 2000; Abciximab Emergent Stroke Treatment Trial 
(AbESTT) Investigators, 2005) in ischemic stroke that demon-
strated a trend toward better clinical outcomes without increas-
ing hemorrhagic complications, a phase III trial was initiated 
(Adams et al., 2008). In addition to a cohort of patients within 
6 h after stroke onset, a special cohort with “wake up strokes” was 
included. The clinical outcome was determined 3 months after 
admission using the mRS and the results were disappointing: 
whilst there was no difference in terms of good clinical outcome 
(33% of placebo-treated patients versus 32% of abciximab-treated 
patients), the rate of symptomatic or fatal intracranial hemor-
rhage increased significantly from 0.5% in the placebo group to 
5.5% via inhibition of the GP-IIb/IIIa complex. As a result, the 
trial was terminated prematurely. In an alternative approach the 
CLEAR trial tested the combination of GP-IIb/IIIa-inhibitors, 
namely eptifibatide (75 μg/kg/BW bolus followed by a 0.75-μg/
kg/BW/min infusion for 2 h), with a low dose rtPA regimen of 
either 0.30 mg/kg or 0.45 mg/kg/BW. The results were compared 
to a standard dose rtPA treatment (0.9 mg/kg; Pancioli et al., 
2008). This approach appeared to be safe, but reports of a  clinical 
 amelioration are still lacking.
In ECASS I, using 1.1 mg/kg/BW rtPA, resulted in a substantial 
number of intracranial hemorrhages, whereas most of the other 
randomized trials used 0.9 mg/kg/BW rtPA. On the other hand a 
lower dosage of rtPA may prove to be comparably effective. Two 
recent Japanese trials have shown that in an Asian population a 
similar outcome may be reached by two thirds of the standard 
rtPA dose in Caucasians (Yamaguchi et al., 2006; Mori et al., 
2010). Meanwhile, the dosage of 0.9 mg/kg/BW has not only been 
proved to be safe in randomized trials but also in clinical practice 
as shown in a large register with 6483 patients (Wahlgren et al., 
2007). At present I.V. thrombolysis with 0.9 mg/kg/BW rtPA has 
been approved in most countries.
Nevertheless even in industrialized countries only the minority 
(Katzan et al., 2004; Albers and Olivet, 2007) of all ischemic stroke 
patients receives rtPA therapy. The major reason for its restricted 
application is its reportedly narrow time window (Lees et al., 2006; 
Harrer, 2010), compounded by the necessity of cerebral imag-
ing to exclude intracerebral hemorrhage. Since the late 1990’s 
(Schlaug et al., 1999), there have been attempts to prolong this 
short therapeutic interval by implementing an approach to predict 
the clinical success of recanalization by imaging the penumbra 
via the so-called “diffusion–perfusion mismatch.” Particularly in 
cases of proximal artery occlusion screening for this mismatch 
may help to increase the proportion of patients eligible for throm-
bolysis and as many as 70–80% show potentially salvageable tissue 
for more than 9 h (Copen et al., 2009). Although several phase 
II-studies (Hacke et al., 2005; Albers et al., 2006; Furlan et al., 
2006) and a retrospective analysis of ATLANTIS, ECASS, and 
NINDS (Thomalla et al., 2006) have confirmed this concept, a 
prospective Phase 3 study that used this approach (Hacke et al., 
2009) failed to demonstrate any benefit.
other fIbrInolytIcs
Because of the disadvantages associated with rtPA there have been 
numerous attempts to find alternative fibrinolytic agents with a 
longer half life and a higher fibrin specificity to facilitate the appli-
cation, to decrease the rates of hemorrhage, and to optimize the 
therapeutic effects. Tenecteplase, another plasminogen activator 
which can be administered in a bolus form has been investigated 
in two phase II trials (Haley et al., 2005, 2010). Both trials, however 
ended more or less at the dose finding level without demonstrating 
superiority or even equivalence to rtPA. Desmoteplase (DSPA), 
originally isolated from the saliva of a vampire bat, is a highly 
fibrin-specific plasminogen activator. Treatment with DSPA is of 
particular interest for thrombolysis after the 3-h time window 
owing to its potential to reduce intracranial hemorrhaging. In 2005, 
findings of the desmoteplase in acute ischemic stroke trial (DIAS 
I) in which I.V. DSPA was administered within 3–9 h of ischemic 
stroke onset in patients with perfusion/diffusion mismatch on MRI, 
were published (Hacke et al., 2005). One hundred and four patients 
with a National Institute of Health Stroke Scale (NIHSS) score of 
4 to 20 were included. Outcome was rated by reperfusion on MRI 
4–8 h after treatment, and clinical improvement after 3 months was 
assessed by using the NIHSS, the modified ranking scale (mRS), and 
Barthel index (BI). A significant advantage was found in terms of 
clinical as well as imaging parameters for DSPA, with the best results 
in the 125-μg/kg/BW group. A year later, the results of the dose 
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The absolute benefit was 15% and the relative benefit 58%. Within 
the last 15 years however only one further randomized trial of 
intra-arterial fibrinolysis (Ogawa et al., 2007) in ischemic stroke has 
been performed. Trials based on directly comparing intra-arterial 
and intravenous thrombolysis in terms of recanalization rates and 
especially in terms of clinical outcome have not been performed at 
all. Thus, intra-arterial fibrinolysis remains an individual treatment 
approach without approval by the FDA and it is not recommended 
generally.
mechanIcal thrombectomy
As an alternative to or as a supplementary tool for systemic or IAT 
mechanical thrombectomy provides higher recanalization rates – 
particularly in patients with occlusion of the carotid-, proximal 
media- or basilaric-artery. Endovascular thrombectomy devices 
remove the occluding clot from the affected vessel mechanically. In 
general three systems can be distinguished: initially distal systems 
have been developed, which permit retrieval of the clot by remov-
ing the thrombus on the way back after the thrombus has been 
passed by the system. A typical device is the mechanical embolus 
removal in cerebral ischemia (MERCI) Retrieval System. Results 
of the Phase 1 MERCI trial were published in 2004 (Gobin et al., 
2004). In this study 28 patients with ICA, MCA, or occlusions of 
the basilar artery were treated within a median time of 6.15 h. In 
43% of all patients, an effective recanalization could be achieved. 
No clinically significant bleeding occurred. Four years later, the 
final data of the Multi MERCI trial, a study with approximately the 
same inclusion criteria as the previous study but with treatment 
within 8 h, were released (Smith et al., 2008). One hundred and 
sixty-four patients were enrolled, and 131 were initially treated 
with the newer generation of MERCI L5 retriever. Recanalization 
by pure mechanical thrombectomy was achieved in 57.3%, whereas 
a recanalization rate of 68% was achieved after additional IAT. Even 
more importantly, the clinical outcome after 90 days was signifi-
cantly (p < 0.001) improved. In turn, this clinical improvement 
correlated closely with success rates of recanalization. A pooled 
analysis of MERCI and Multi MERCI with a subinvestigation of 
patients with an acute stoke from intracranial ICA-occlusion con-
firmed this observation (Flint et al., 2007). Because of its promising 
results the MERCI Retriever was the first FDA-approved technical 
device used to restore blood flow.
Alternatively to this method, a clot may be removed from the 
proximal side, e.g., by using aspiration techniques. In the process, 
the necessity of perforating the thrombus can be avoided, thereby 
reducing the risk of thrombus fragmentation and associated distal 
emboli. However a comparison of both methods (i.e., retrieval 
versus aspiration) reveals a higher recanalization rate for the distal 
thrombectomy systems (Gralla et al., 2006; see Table 1).
An even more advanced device is the Penumbra Stroke System, 
which was licensed by the FDA after it achieved a recanalization 
rate of 100% in a smaller pilot study (Bose et al., 2008) and even 
81.6% in a subsequent larger prospective trial (Penumbra Pivotal 
Stroke Trial Investigators, 2009). In addition to an aspiration sys-
tem, this device includes a mechanism for grasping the thrombus 
directly. In a similar manner, stents like the Solitaire-remodeling 
device, are capable of being delivered immediately to the side of 
the thrombus and removing the clot, while at the same time, being 
I.a.-thrombolysIs (Iat)
In IAT fibrinolytic drugs are applied directly into the occluding 
thrombus using microcatheter delivery systems. By means of this 
minimally invasive technique high local drug concentrations with 
lower systemic concentrations can be achieved, which, at least theo-
retically, reduces the risk of extracranial hemorrhagic complications. 
In addition this method provides precise imaging of the arterial 
anatomy, pathology, and collateral circulation. Furthermore, IAT 
includes the option of applying additional devices to disrupt the 
clot mechanically. In retrospective clinical case studies, IAT yielded 
higher rates of recanalization than I.V. therapy (Alexandrov et al., 
2002; Higashida et al., 2003), with an estimated average recanaliza-
tion rate of 70%, which has been confirmed in a recent meta-anal-
ysis (Lee et al., 2010). The method’s chief disadvantage, however, is 
the lag time during which fibrinolysis is initiated. The delay can be 
attributed to logistic as well as procedure-related technical reasons 
and is closely related to the progression of neuronal cell death in the 
ischemic brain, which has been shown to be strictly time dependent. 
Moreover the most effective thrombolytic drug for IAT has never 
been adequately tested. Although in the prolyse in acute cerebral 
thromboembolism (PROACT)-trials recombinant prourokinase 
has been used, r-proUK is unavailable routinely because it lacks 
FDA approval. As such, most recent investigations have utilized 
rtPA for practical reasons. Additionally, the ideal dosage for both 
drugs in IAT has not been tested. Patients were treated with either 
urokinase in a dosage up to 2 million U or with rtPA in a dosage 
up to 90 mg within 6 h of symptom onset. Comparisons between 
these trials are complicated because of the broad range of inclu-
sion and exclusion criteria. The PROACT I study in 1995 was the 
first randomized double-blinded multicenter trial, in which safety, 
recanalization frequency, and clinical efficacy of IAT with r-proUK 
were compared with a placebo in patients with symptomatic MCA 
occlusion in a 6-h time window (del Zoppo et al., 1998). Eligible 
patients were randomized to receive a placebo or a fixed dose of 
6 mg r-proUK administered over a 2-h period in the proximal 
third of the thrombus or close to the clot within the M1-segment. 
Mechanical disruption of the thrombus was prohibited. The degree 
of the recanalization was determined at the end of the procedure. 
Subsequently, patients were given I.V. heparin for 4 h. Because of 
severe hemorrhage rates in the first 16 patients with a high dose 
heparin regime, the heparin dose was later decreased. A CCT was 
performed in all patients after 24 h to control bleeding. Clinical 
outcome was rated by blinded physicians by the NIHSS, the mRS, 
and the BI 7, 30, and 90 days after treatment. Out of 40 patients, 
26 received r-proUK, and 14 a placebo. In summary, there was 
a 10–12% absolute increase in positive outcomes in patients 
treated with r-proUK compared to those in the placebo group. 
Interestingly, heparin reduction resulted in a decreased recanali-
zation rate from 82 to 40%, and, at the same time, hemorrhagic 
side-effects were also lower. The rate of symptomatic bleedings was 
15% in the r-proUK group compared to 7% in the placebo group. 
Consequently in PROACT II (Furlan et al., 1999) the dosage of 
r-proUK was increased to 9 mg to improve the recanalization rates 
whereas only low dose heparin was administered. One hundred 
and eighty patients were randomized and 121 patients received 
r-proUK. Under this regimen, recanalization rate was 66% with an 
symptomatic hemorrhage rate of 10% for r-proUK treated patients. 
Frontiers in Neurology | Endovascular and Interventional Neurology  February 2011 | Volume 2 | Article 7 | 4
Knauer and Huber Bridging fibrinolysis in ischemic stroke
management of stroke single arm trial (IMS I) from 2004 (IMS 
Study Investigators, 2004). In this study the same I.V.-rtPA dosage 
was used, but the initial I.V.-bolus was slightly increased to 15% 
and the consecutive intra-arterial dosage was adapted to 22 mg 
rtPA. The 3-months outcome in these 80 subjects was matched to 
the outcome in the NINDS rtPA Stroke trial thus making it pos-
sible to compare standard intravenous fibrinolysis (I.V.-rtPA) with 
the I.V./I.A.-approach. Once again the asymptomatic hemorrhage 
rates increased significantly with the combination therapy (43 ver-
sus 6%), whereas symptomatic bleedings did not differ in between 
these two trials. The clinical outcome of the combined therapy did 
not differ from the purely intravenous procedure, although both 
methods substantially improved the clinical outcome compared to 
the placebo-treated patients in NINDS. In the subsequent single 
arm Interventional Management of Stroke II Study (IMS II Trial 
Investigators, 2007), 81 subjects with even more severe strokes 
and a median baseline NIHSS score of 19 were included. Fifty-five 
patients received the combined I.V./IAT. The results were similar to 
the IMS I trial with a mRS of 0–2 in 46% after 3 months, but the 
rate of symptomatic intracranial hemorrhages was increased from 
6.3 in IMS I to 9.9% in IMS II. Nonetheless, it should be borne in 
mind that in the 2007 study, in 36 of the 55 I.A.-treated patients the 
approach was complemented by a small-vessel ultrasound infusion 
system (EKOS) to potentially accelerate thrombolysis. In a more 
clinical setting the “classical” bridging-version has been tested in 
both carotid artery distribution strokes (Ernst et al., 2000) and in 
very severely affected patients (Zaidat et al., 2002). In the event of 
persisting deficits, the I.V.-approach was shifted after 30 min to a 
IAT until the clot completely resolved or up to a maximum dosage 
of 0.9 mg/kg/BW. Although a recanalization could be achieved in 
four out of five patients with an ICA-occlusion, the mortality rate 
remained as high as 50%. Interestingly, an upside-down pathway has 
also been conducted. Keris et al. (2001) applied primarily IAT fol-
lowed by I.V.-thrombolyis. In that study 45 patients with severe acute 
ischemic stroke within 6 h after symptom onset were investigated. 
Only 12 of them were randomized to the fibrinolysis group, whereas 
completely retrievable (Henkes et al., 2003; Castano et al., 2009b). 
Although only small case series are available, the Solitaire stent 
might be superior (Castano et al., 2009b) to distal retraction devices 
owing to its simplicity and speed, as well as its relatively protective 
properties for the vessel wall. In any event, a comparison of several 
recanalization procedures (Rha et al., 2007; Nogueira et al., 2009) 
and thrombectomy devices (Castano et al., 2009a, Serna-Candel 
et al., 2010) yields the highest recanalization success rates for distal 
thrombectomy devices, one the one hand, and the Solitaire stent 
on the other (see Table 1).
brIdgIng therapy
I.v./I.a.-combInIng I.v. and I.a.-rtpa
Time delay resulting from initiation and preparation of IAT and 
mechanical devices is the main drawback of this technique com-
pared with I.V. thrombolysis.
A potential advantage of a combined I.V./I.A. approach is the rapid 
initiation and easy handling of I.V. treatment, combined with the 
potentially higher recanalization rates associated with I.A. therapy, 
to optimize clinical outcome. Lewandowski et al. (1999) published 
the findings of the emergency management stroke (EMS) Bridging 
Trial. This was a double-blinded, randomized, placebo-controlled 
multicenter trial that compared pure IAT to an I.V./I.A. approach. A 
total of 35 patients with acute ischemic stroke within 3 h after symp-
tom onset were randomized. They received either a loading dose of 
0.6 mg/kg/BW I.V. rtPA with 10% as bolus application (17 patients) 
or a placebo (18 patients) followed immediately by cerebral arte-
riography and local I.A.-rtPA with a maximal dose of 20 mg rtPA. 
The combined approach yielded significantly higher recanalization 
rates (55% I.V./I.A. versus 10% placebo/IAT) without producing a 
clinically significant improvement as measured by NIHSS, BI, mRS, 
and Glasgow Outcome Scale at days 1 and 7 and after 3 months. 
The obviously higher mortality rate in the I.V./I.A.-group seemed 
to be attributable to the very low numbers of patients included. In 
a very similar (but not placebo-controlled) approach, 80 severely 
affected patients (NIHSS ≥ 10) were treated in the  interventional 
Table 1 | Recanalization rate upon different procedures.
Recanalization method n (pts.)  Recanalization Patients with  Studies/references 
   rate in % ICA-occlusions in %
Spontaneous (placebo) 253 24.1 NA Rha et al. (2007)
I.V. 474 46.2 NA Rha et al. (2007)
I.V. + tUS 63 46 0 Alexandrov et al. (2004)
Bridging 95 52.6 20.5 IMS II Trial Investigators (2007, parts);  
    IMS Study Investigators (2004);  
    Lewandowski et al. (1999)
Bridging + eUS 33 72.7 NA IMS II Trial Investigators (2007, parts)
I.A. (rp)UK 165 67.3 0 Furlan et al. (1999); Ogawa et al. (2007)
MERCI + I.A. rtPA 164 68.2 30 Smith et al. (2008)
Penumbra 125 81.6 18 Penumbra Pivotal Stroke
    Trial Investigators (2009)
Solitaire AB 20 90 40 Castano et al. (2009a)
tUS, transcranial ultrasound; eUS, endovascular ultrasound; NA, not applicable. Due to the importance of the proximal occlusion site, the percentage of ICA-occlusion 
is separately listed. Recanalization is due to a grading of two or three in the thrombolysis in myocardial infarction (TIMI) or thrombolysis in cerebral infarction (TICI) 
score beside Alexandrov et al., (2004), who used the thrombolysis in brain ischemia (TIBI) classification.
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fibrinolytic dosages compared to the PROACT and IMS-1 and -2 tri-
als. Unfortunately the results of the randomized IMS-3 trial (Khatri 
et al., 2008), which includes the use of two different catheter devices, 
will be a long time in coming.
conclusIon
At present, intravenous fibrinolysis is the approved standard therapy 
in patients with acute ischemic stroke. Nevertheless, only a minority 
of all patients is treated with I.V.-rtPA, whereas recanalization – 
the most crucial factor for the clinical outcome – succeeds in only 
50% of patients receiving this therapy. Intra-arterial procedures 
yield considerably higher recanalization rates for I.A.-rtPA and 
particularly for mechanical thrombectomy devices, although their 
clinical superiority over the systemic approach may depend on the 
time lag associated with the more complex technique. Accordingly, 
bridging this time lag by means of intravenous rtPA is a useful 
strategy. Most available data from randomized trials recommend 
a dosage of 0.6 mg/kg/BW rtPA and a time lag of 30 min as “intra-
venous to intra-arterial” needle time (Lewandowski et al., 1999; 
Ernst et al., 2000; Zaidat et al., 2002; IMS Study Investigators, 2004; 
IMS II Trial Investigators, 2007). Although superior clinical out-
comes have not been proved yet, this regimen seems to be reason-
able. Treatment confined to a dosage of 0.6 mg/kg/BW I.V.-rtPA is 
effective, at least in an Asian population (Yamaguchi et al., 2006; 
Mori et al., 2010), whereas the incidence of intracranial hemor-
rhages remains unchanged even when intra-arterial fibrinolysis 
is also performed. The 30-min time lag between I.V.-rtPA and the 
initiation of intra-arterial procedures is short, but this interval has 
to be as short as possible. In the event that, for logistical reasons, 
it is necessary to exceed the 30-min time limit, an intravenous 
fibrinolysis with 0.9 mg/kg/BW rtPA should be administered. The 
data to date in the field (Flint et al., 2007; Shaltoni et al., 2007) does 
not indicate that there are higher symptomatic bleeding rates if an 
intra-arterial procedure is performed immediately after a full dose 
I.V.-rtPA fibrinolysis.
In general subsequent endovascular intervention should be 
aimed at recanalizing persisting vessel-occlusions, as performed 
in several recent studies (Eckert et al., 2005; Mangiafico et al., 2005; 
Flint et al., 2007; Smith et al., 2008; Castano et al., 2009a; Mazighi 
et al., 2009). Depending on the preceding intravenous rtPA dos-
age, we propose a strategy based predominantly on a combination 
of an intra-arterial fibrinolysis and a mechanical device after an 
intravenous dosage of 0.6 mg/kg/BW rtPA, whereas a almost “pure” 
mechanical intervention, for example with the Solitaire stent, 
should be preferred following an intravenous full dose rtPA regi-
men. However, in our experience recanalization by an I.A. approach 
without any additional fibrinolytic agent is difficult. Therefore a 
small amount of rtPA is always used in our center.
Finally, all these approaches have to be able to demonstrate 
their clinical superiority when comparing their results with the 
gold standard, which up to now remains I.V.-rtPA. Therefore a 
randomized trial comparing intravenous fibrinolysis with a bridg-
ing therapy is desperately needed. In this study patients with a 
proximal artery occlusion and a large penumbra according to the 
MRI mismatch criteria should be treated either intravenously or 
by a bridging regimen, including intra-arterial fibrinolysis and/or 
mechanical thrombectomy.
33 patients were randomized to the conventional treatment group. 
Patients in the first group received 25 mg rtPA I.V. over 60 min after 
an intra-arterial injection of 25 mg rtPA over 5–10 min without 
mechanical clot disruption. Although clinical outcomes following 
treatment assessment at 1 and at 12 months were better, these results 
are clearly restricted by the very low number of patients studied.
brIdgIng extended – I.v./I.a-thrombolysIs and beyond
Despite inconclusive results and an astonishing lack of even a single 
study comparing a combined I.V./I.A. approach to the standard 
I.V.-rtPA scheme in a randomized trial, the “conventional” I.V./I.A.-
combination approach has been extended in several ways. Some 
investigators used urokinase (UK) in addition to rtPA for synergis-
tic and complementary effects. For example, in 24 patients with a 
median baseline NIHSS score of 18, Lee et al. (2004), administered 
a full dose I.V.-rtPA (0.9 mg/kg/BW) treatment followed by I.A. UK 
(300000 U initially, with a maximum overall dose of 1000000 U). 
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Shaltoni et al. (2007), in a retrospective data set from 69 patients 
with a median pretreatment NIHSS score of 18, showed that a con-
secutive IAT within a median time of 105 min after finalizing a full 
dose I.V.-treatment did not necessarily result in higher symptomatic 
intracranial hemorrhage rates. However, a direct comparison of 
the intracranial hemorrhage frequencies is difficult, as this study 
included mainly intra-arterial treatment with reteplase. Moreover 
the few patients treated with alteplase and UK received even lower 
Frontiers in Neurology | Endovascular and Interventional Neurology  February 2011 | Volume 2 | Article 7 | 6
Knauer and Huber Bridging fibrinolysis in ischemic stroke
selected by MRI perfusion–diffusion 
weighted imaging or perfusion CT 
(DIAS-2): a prospective, randomised, 
double-blind, placebo-controlled 
study. Lancet Neurol. 8, 141–150.
Hacke, W., Kaste, M., Bluhmki, E., 
Brozman, M., Davalos, A., Guidetti, 
D., Larrue, V., Lees, K. R., Medeghri, 
Z., Machnig, T., Schneider, D., von 
Kummer, R., Wahlgren, N., and 
Toni, D. (2008). Thrombolysis with 
alteplase 3 to 4.5 hours after acute 
ischemic stroke. N. Engl. J. Med. 359, 
1317–1329.
Hacke, W., Kaste, M., Fieschi, C., Toni, D., 
Lesaffre, E., von Kummer, R., Boysen, 
G., Bluhmki, E., Hoxter, G., and 
Mahagne, M. H. (1995). Intravenous 
thrombolysis with recombinant tissue 
plasminogen activator for acute hemi-
spheric stroke. The European coopera-
tive acute stroke study (ECASS). JAMA 
274, 1017–1025.
Hacke, W., Kaste, M., Fieschi, C., von 
Kummer, R., Davalos, A., Meier, D., 
Larrue, V., Bluhmki, E., Davis, S., 
Donnan, G., Schneider, D., Diez-
Tejedor, E., and Trouillas, P. (1998). 
Randomised double-blind placebo-
controlled trial of thrombolytic 
therapy with intravenous alteplase 
in acute ischaemic stroke (ECASS II). 
Second European-Australasian acute 
stroke study investigators. Lancet 352, 
1245–1251.
Haley, E. C., Jr., Lyden, P. D., Johnston, 
K. C., and Hemmen, T. M. (2005). A 
pilot dose-escalation safety study of 
tenecteplase in acute ischemic stroke. 
Stroke 36, 607–612.
Haley, E C., Jr., Thompson, J. L., Grotta, 
J. C., Lyden, P. D., Hemmen, T. G., 
Brown, D. L., Fanale, C., Libman, 
R., Kwiatkowski, T. G., Llinas, R. 
H., Levine, S. R., Johnston, K. C., 
Buchsbaum, R., Levy, G., and Levin, 
B. (2010). Phase IIB/III trial of ten-
ecteplase in acute ischemic stroke: 
results of a prematurely terminated 
randomized clinical trial. Stroke 41, 
707–711.
Harrer, J. U. (2010). Clinical applicabil-
ity and the perfusion–diffusion mis-
match theory: not yet a perfect match. 
Neurology 75, 1034–1035.
Heiss, W. D., Grond, M., Thiel, A., von 
Stockhausen, H. M., Rudolf, J., 
Ghaemi, M., Lottgen, J., Stenzel, C., 
and Pawlik, G. (1998). Tissue at risk 
of infarction rescued by early reper-
fusion: a positron emission tomog-
raphy study in systemic recombinant 
tissue plasminogen activator throm-
bolysis of acute stroke. J. Cereb. Blood 
Flow Metab. 18, 1298–1307.
Henkes, H., Flesser, A., Brew, S., 
Miloslavski, E., Doerfler, A., Felber, S., 
Monstadt, H., and Kuehne, D. (2003). 
Flint, A. C., Duckwiler, G. R., Budzik, R. 
F., Liebeskind, D. S., and Smith, W. S. 
(2007). Mechanical thrombectomy 
of intracranial internal carotid occlu-
sion: pooled results of the MERCI and 
Multi MERCI Part I trials. Stroke 38, 
1274–1280.
Furlan, A., Higashida, R., Wechsler, L., 
Gent, M., Rowley, H., Kase, C., Pessin, 
M., Ahuja, A., Callahan, F., Clark, W. 
M., Silver, F., and Rivera, F. (1999). 
Intra-arterial prourokinase for acute 
ischemic stroke. The PROACT II 
study: a randomized controlled trial. 
Prolyse in acute cerebral thromboem-
bolism. JAMA 282, 2003–2011.
Furlan, A. J., Eyding, D., Albers, G. W., 
Al-Rawi, Y., Lees, K. R., Rowley, H. A., 
Sachara, C., Soehngen, M., Warach, S., 
and Hacke, W. (2006). Dose escalation 
of desmoteplase for acute ischemic 
stroke (DEDAS): evidence of safety 
and efficacy 3 to 9 hours after stroke 
onset. Stroke 37, 1227–1231.
Gobin, Y. P., Starkman, S., Duckwiler, G. 
R., Grobelny, T., Kidwell, C. S., Jahan, 
R., Pile-Spellman, J., Segal, A., Vinuela, 
F., and Saver, J. L. (2004). MERCI 1: a 
phase 1 study of mechanical embolus 
removal in cerebral ischemia. Stroke 
35, 2848–2854.
Gralla, J., Schroth, G., Remonda, L., 
Nedeltchev, K., Slotboom, J., and 
Brekenfeld, C. (2006). Mechanical 
thrombectomy for acute ischemic 
stroke: thrombus-device interaction, 
efficiency, and complications in vivo. 
Stroke 37, 3019–3024.
Hacke, W., Albers, G., Al-Rawi, Y., 
Bogousslavsky, J., Davalos, A., Eliasziw, 
M., Fischer, M., Furlan, A., Kaste, M., 
Lees, K. R., Soehngen, M., and Warach, 
S. (2005). The desmoteplase in acute 
ischemic stroke trial (DIAS): a phase 
II MRI-based 9-hour window acute 
stroke thrombolysis trial with intrave-
nous desmoteplase. Stroke 36, 66–73.
Hacke, W., Donnan, G., Fieschi, C., Kaste, 
M., von Kummer, R., Broderick, J. 
P., Brott, T., Frankel, M., Grotta, J. 
C., Haley, E. C., Jr., Kwiatkowski, T., 
Levine, S. R., Lewandowski, C., Lu, 
M., Lyden, P., Marler, J. R., Patel, S., 
Tilley. B. C., Albers, G., Bluhmki, E., 
Wilhelm, M., and Hamilton, S. (2004). 
Association of  outcome with early 
stroke treatment: pooled analysis of 
ATLANTIS, ECASS, and NINDS rt-PA 
stroke trials. Lancet 363, 768–774.
Hacke, W., Furlan, A. J., Al-Rawi, Y., 
Davalos, A., Fiebach, J. B., Gruber, 
F., Kaste, M., Lipka, L. J., Pedraza, S., 
Ringleb, P. A., Rowley, H. A., Schneider, 
D., Schwamm, L. H., Leal, J. S., Sohngen, 
M., Teal, P. A., Wilhelm-Ogunbiyi, 
K., Wintermark, M., and Warach, S. 
(2009). Intravenous desmoteplase in 
patients with acute ischaemic stroke 
AB device for mechanical thrombec-
tomy when merci clot retriever has 
failed to remove the clot. A case report. 
Interv. Neuroradiol. 15, 209–214.
Christou, I., Alexandrov, A. V., Burgin, 
W. S., Wojner, A. W., Felberg, R. A., 
Malkoff, M., and Grotta, J. C. (2000). 
Timing of recanalization after tis-
sue plasminogen activator therapy 
determined by transcranial dop-
pler correlates with clinical recov-
ery from ischemic stroke. Stroke 31, 
1812–1816.
Copen, W. A., Rezai Gharai, L., Barak, E. 
R., Schwamm, L. H., Wu, O., Kamalian, 
S., Gonzalez, R. G., and Schaefer, P. W. 
(2009). Existence of the diffusion-per-
fusion mismatch within 24 hours after 
onset of acute stroke: dependence on 
proximal arterial occlusion. Radiology 
250, 878–886.
Cura, F. A., Bhatt, D. L., Lincoff, A. M., 
Kapadia, S. R., L’Allier, P. L., Ziada, 
K. M., Wolski, K. E., Moliterno, D. J., 
Brener, S. J., Ellis, S. G., and Topol, E. 
J. (2000). Pronounced benefit of coro-
nary stenting and adjunctive platelet 
glycoprotein IIb/IIIa  inhibition in 
complex atherosclerotic lesions. 
Circulation 102, 28–34.
del Zoppo, G. J., Higashida, R. T., Furlan, 
A. J., Pessin, M. S., Rowley, H. A., and 
Gent, M. (1998). PROACT: a phase II 
randomized trial of recombinant pro-
urokinase by direct arterial delivery in 
acute middle cerebral artery stroke. 
PROACT investigators. Prolyse in 
acute cerebral thromboembolism. 
Stroke 29, 4–11.
Donnan, G. A., Davis, S. M., Chambers, B. 
R., Gates, P. C., Hankey, G. J., McNeil, 
J. J., Rosen, D., Stewart-Wynne, E. G., 
and Tuck, R. R. (1996). Streptokinase 
for acute ischemic stroke with rela-
tionship to time of administration: 
Australian streptokinase (ASK) trial 
study group. JAMA 276, 961–966.
Eckert, B., Koch, C., Thomalla, G., 
Kucinski, T., Grzyska, U., Roether, J., 
Alfke, K., Jansen, O., and Zeumer, H. 
(2005). Aggressive therapy with intra-
venous abciximab and intra-arterial 
rtPA and additional PTA/stenting 
improves clinical outcome in acute 
vertebrobasilar occlusion: combined 
local fibrinolysis and intravenous 
abciximab in acute vertebrobasilar 
stroke treatment (FAST): results 
of a multicenter study. Stroke 36, 
1160–1165.
Ernst, R., Pancioli, A., Tomsick, T., 
Kissela, B., Woo, D., Kanter, D., 
Jauch, E., Carrozzella, J., Spilker, J., 
and Broderick, J. (2000). Combined 
intravenous and intra-arterial recom-
binant tissue plasminogen activator 
in acute ischemic stroke. Stroke 31, 
2552–2557.
references
Abciximab Emergent Stroke Treatment 
Trial (AbESTT) Investigators. (2005). 
Emergency administration of abcixi-
mab for treatment of patients with acute 
ischemic stroke: results of a randomized 
phase 2 trial. Stroke 36, 880–890.
Abciximab in Ischemic Stroke 
Investigators. (2000). Abciximab in 
acute ischemic stroke: a randomized, 
double-blind, placebo-controlled, 
dose-escalation study. Stroke 31, 
601–609.
Adams, H. P., Jr. Effron, M. B., Torner, J., 
Davalos, A., Frayne, J., Teal, P., Leclerc, 
J., Oemar, B., Padgett, L., Barnathan, E. 
S., and Hacke, W. (2008). Emergency 
administration of abciximab for treat-
ment of patients with acute ischemic 
stroke: results of an international 
phase III trial: abciximab in emergency 
treatment of stroke trial (AbESTT-II). 
Stroke 39, 87–99.
Albers, G. W., and Olivot, J. M. (2007). 
Intravenous alteplase for ischaemic 
stroke. Lancet 369, 249–250.
Albers, G. W., Thijs, V. N., Wechsler, L., 
Kemp, S., Schlaug, G., Skalabrin, E., 
Bammer, R., Kakuda, W., Lansberg, M. 
G., Shuaib, A., Coplin, W., Hamilton, S., 
Moseley, M., and Marks, M. P. (2006). 
Magnetic resonance imaging profiles 
predict clinical response to early reper-
fusion: the diffusion and perfusion 
imaging evaluation for understanding 
stroke evolution (DEFUSE) study. Ann. 
Neurol. 60, 508–517.
Alexandrov, A. V., and Grotta, J. C. (2002). 
Arterial reocclusion in stroke patients 
treated with intravenous tissue plas-
minogen activator. Neurology 59, 
862–867.
Alexandrov, A. V., Molina, C. A., Grotta, 
J. C., Garami, Z., Ford, S. R., Alvarez-
Sabin, J., Montaner, J., Saqqur, M., 
Demchuk, A. M., Moye, L. A., Hill, 
M. D., and Wojner, A. W. (2004). 
Ultrasound-enhanced systemic 
thrombolysis for acute ischemic stroke. 
N. Engl. J. Med. 351, 2170–2178.
Bose, A., Henkes, H., Alfke, K., Reith, W., 
Mayer, T. E., Berlis, A., Branca, V., and 
Sit, S. P. (2008). The Penumbra System: 
a mechanical device for the treatment 
of acute stroke due to thromboem-
bolism. AJNR Am. J. Neuroradiol. 29, 
1409–1413.
Castano, C., Dorado, L., Guerrero, C., 
Millan, M., Gomis, M., Perez de la 
Ossa, N., Castellanos, M., Garcia, M. 
R., Domenech, S., and Davalos, A. 
(2009a). Mechanical thrombectomy 
with the Solitaire AB device in large 
artery occlusions of the anterior 
circulation: a pilot study. Stroke 41, 
1836–1840.
Castano, C., Serena, J., and Davalos, A. 
(2009b). Use of the new Solitaire (TM) 
www.frontiersin.org February 2011 | Volume 2 | Article 7 | 7
Knauer and Huber Bridging fibrinolysis in ischemic stroke
treatment for acute stroke: an open field 
to begin. Neurologia 25, 273–278.
Shaltoni, H. M., Albright, K. C., Gonzales, 
N. R., Weir, R. U., Khaja, A. M., Sugg, R. 
M., Campbell, M. S., IIIrd, Cacayorin, E. 
D., Grotta, J. C., and Noser, E. A. (2007). 
Is intra-arterial thrombolysis safe after 
full-dose intravenous recombinant 
tissue plasminogen activator for acute 
ischemic stroke? Stroke 38, 80–84.
Sherman, D. G., Atkinson, R. P., 
Chippendale, T., Levin, K. A., Ng, K., 
Futrell, N., Hsu, C. Y., and Levy, D. E. 
(2000). Intravenous ancrod for treat-
ment of acute ischemic stroke: the 
STAT study: a randomized control-
led trial. Stroke treatment with ancrod 
trial. JAMA 283, 2395–2403.
Smith, W. S., Sung, G., Saver, J., Budzik, R., 
Duckwiler, G., Liebeskind, D. S., Lutsep, 
H. L., Rymer, M. M., Higashida, R. T., 
Starkman, S., Gobin, Y. P., Frei, D., 
Grobelny, T., Hellinger, F., Huddle, D., 
Kidwell, C., Koroshetz, W., Marks, M., 
Nesbit, G., and Silverman, I. E. (2008). 
Mechanical thrombectomy for acute 
ischemic stroke: final results of the multi 
MERCI trial. Stroke 39, 1205–1212.
Thomalla, G., Schwark, C., Sobesky, J., 
Bluhmki, E., Fiebach, J. B., Fiehler, J., 
Zaro Weber, O., Kucinski, T., Juettler, 
E., Ringleb, P. A., Zeumer, H., Weiller, 
C., Hacke, W., Schellinger, P. D., 
and Rother, J. (2006). Outcome and 
symptomatic bleeding  complications 
of intravenous thrombolysis within 6 
hours in MRI-selected stroke patients: 
comparison of a German multi-
center study with the pooled data of 
ATLANTIS, ECASS, and NINDS tPA 
trials. Stroke 37, 852–858.
Tomsick, T., Brott, T., Barsan, W., Broderick, 
J., Haley, E. C., Spilker, J., and Khoury, J. 
(1996). Prognostic value of the hyper-
dense middle cerebral artery sign and 
stroke scale score before ultraearly 
thrombolytic therapy. AJNR Am. J. 
Neuroradiol. 17, 79–85.
Wahlgren, N., Ahmed, N., Davalos, A., 
Ford, G. A., Grond, M., Hacke, W., 
Hennerici, M. G., Kaste, M., Kuelkens, 
S., Larrue, V., Lees, K. R., Roine. R. O., 
Soinne, L., Toni, D., and Vanhooren, G. 
(2007). Thrombolysis with alteplase 
for acute ischaemic stroke in the safe 
implementation of thrombolysis 
in stroke-monitoring study (SITS-
MOST): an observational study. 
Lancet 369, 275–282.
Wahlgren, N., Ahmed, N., Davalos, A., 
Hacke, W., Millan, M., Muir, K., Roine, 
R. O., Toni, D., and Lees, K. R. (2008). 
Thrombolysis with alteplase 3–4.5 h 
after acute ischaemic stroke (SITS-
ISTR): an observational study. Lancet 
372, 1303–1309.
Wardlaw, J. M., Zoppo, G., Yamaguchi, T., 
and Berge, E. (2003). Thrombolysis 
ebral artery occlusion: Japan alteplase 
clinical trial II (J-ACT II). Stroke 41, 
461–465.
Mori, E., Yoneda, Y., Tabuchi, M., Yoshida, 
T., Ohkawa, S., Ohsumi, Y., Kitano, K., 
Tsutsumi, A., and Yamadori, A. (1992). 
Intravenous recombinant tissue plas-
minogen activator in acute carotid 
artery territory stroke. Neurology 42, 
976–982.
National Institute of Neurological 
Disorders, and Stroke rt-PA Stroke 
Study Group. (1995). Tissue plasmino-
gen activator for acute ischemic stroke. 
N. Engl. J. Med. 333, 1581–1587.
Nogueira, R. G., Yoo, A. J., Buonanno, F. S., 
and Hirsch, J. A. (2009). Endovascular 
approaches to acute stroke, part 2: a 
comprehensive review of studies and 
trials. AJNR Am. J. Neuroradiol. 30, 
859–875.
Ogawa, A., Mori, E., Minematsu, K., 
Taki, W., Takahashi, A., Nemoto, S., 
Miyamoto, S., Sasaki, M., and Inoue, 
T. (2007). Randomized trial of intraar-
terial infusion of urokinase within 6 
hours of middle cerebral artery stroke: 
the middle cerebral artery embolism 
local fibrinolytic intervention trial 
(MELT) Japan. Stroke 38, 2633–2639.
Pancioli, A. M., Broderick, J., Brott, T., 
Tomsick, T., Khoury, J., Bean, J., Del 
Zoppo, G., Kleindorfer, D., Woo, D., 
Khatri, P., Castaldo, J., Frey, J., Gebel, J., 
Jr., Kasner, S., Kidwell, C., Kwiatkowski, 
T., Libman, R, Mackenzie R., Scott, 
P., Starkman, S., and Thurman, R. J. 
(2008). The combined approach to 
lysis utilizing eptifibatide and rt-PA 
in acute ischemic stroke: the CLEAR 
stroke trial. Stroke 39, 3268–3276.
Penumbra Pivotal  Stroke Trial 
Investigators. (2009). The penum-
bra pivotal stroke trial: safety and 
effectiveness of a new generation of 
mechanical devices for clot removal 
in intracranial large vessel occlusive 
disease. Stroke 40, 2761–2768.
Rha, J. H., and Saver, J. L. (2007). The 
impact of recanalization on ischemic 
stroke outcome: a meta-analysis. 
Stroke 38, 967–973.
Ringelstein, E. B., Biniek, R., Weiller, 
C., Ammeling, B., Nolte, P. N., and 
Thron, A. (1992). Type and extent 
of hemispheric brain infarctions and 
clinical outcome in early and delayed 
middle cerebral artery recanalization. 
Neurology 42, 289–298.
Schlaug, G., Benfield, A., Baird, A. E., 
Siewert, B., Lovblad, K. O., Parker, 
R. A., Edelman, R. R., and Warach, 
S. (1999). The ischemic penumbra: 
operationally defined by diffusion 
and perfusion MRI. Neurology 53, 
1528–1537.
Serna-Candel, C., Lopez-Ibor, L., and 
Matias-Guiu, J. (2010). Endovascular 
Levy, D. E., Del Zoppo, G. J., Demaerschalk, 
B. M., Demchuk, A. M., Diener, H. C., 
Howard, G., Kaste, M., Pancioli, A. M., 
Ringelstein, E. B., Spatareanu, C., and 
Wasiewski, W. W. (2009). Ancrod 
in acute ischemic stroke: results of 
500 subjects beginning treatment 
within 6 hours of stroke onset in the 
ancrod stroke program. Stroke 40, 
3796–3803.
Lewandowski, C. A., Frankel, M., Tomsick, 
T. A., Broderick, J., Frey, J., Clark, 
W., Starkman, S., Grotta, J., Spilker, 
J., Khoury, J., and Brott, T. (1999). 
Combined intravenous and intra-arte-
rial r-TPA versus intra-arterial therapy 
of acute ischemic stroke: emergency 
management of stroke (EMS) bridg-
ing trial. Stroke 30, 2598–2605.
Liebeskind, D. S., Pollard, J. R., Schwartz, 
E. D., Cucchiara, B. L., McGarvey, 
M. L., and Hurst, R. W. (2002). 
Vertebrobasilar thrombolysis with 
intravenous tirofiban: case report. J. 
Thromb. Thrombolysis 13, 81–84.
Mangiafico, S., Cellerini, M., Nencini, P., 
Gensini, G., and Inzitari, D. (2005). 
Intravenous glycoprotein IIb/IIIa 
inhibitor (tirofiban) followed by intra-
arterial urokinase and mechanical 
thrombolysis in stroke. AJNR Am. J. 
Neuroradiol. 26, 2595–2601.
Martin-Schild, S., Shaltoni, H., Abraham, 
A. T., Barreto, A. D., Hallevi, H., 
Gonzales, N. R., Grotta, J. C., and 
Savitz, S. I. (2009). Safety of eptifi-
batide for subcortical stroke progres-
sion. Cerebrovasc. Dis. 28, 595–600.
MAST-E. (1996). Thrombolytic therapy 
with streptokinase in acute ischemic 
stroke. The multicenter acute stroke 
trial – Europe study group. N. Engl. J. 
Med. 335, 145–150.
MAST-I. (1995). Randomised control-
led trial of streptokinase, aspirin, and 
combination of both in treatment of 
acute ischaemic stroke. Multicentre 
acute stroke trial – Italy (MAST-I) 
group. Lancet 346, 1509–1514.
Mazighi, M., Serfaty, J. M., Labreuche, J., 
Laissy, J. P., Meseguer, E., Lavallee, P. 
C., Cabrejo, L., Slaoui, T., Guidoux, 
C., Lapergue, B., Klein, I. F., Olivot, 
J. M., Abboud, H., Simon, O., Niclot, 
P., Nifle, C., Touboul, P. J., Raphaeli, 
G., Gohin, C., Claeys, E. S., and 
Amarenco, P. (2009). Comparison of 
intravenous alteplase with a combined 
intravenous-endovascular approach 
in patients with stroke and confirmed 
arterial occlusion (RECANALISE 
study): a prospective cohort study. 
Lancet Neurol. 8, 802–809.
Mori, E., Minematsu, K., Nakagawara, 
J., Yamaguchi, T., Sasaki, M., and 
Hirano, T. (2010). Effects of 0.6 mg/
kg intravenous alteplase on vascular 
and clinical outcomes in middle cer-
A novel microcatheter-delivered, 
highly-flexible and fully-retrievable 
stent, specifically designed for intrac-
ranial use. Technical note. Interv. 
Neuroradiol. 9, 391–393.
Higashida, R., Furlan, A., Roberts, H., 
Tomsick, T., Connors, B., Barr, J., 
Dillon, W., Warach, S., Broderick, J., 
Tilley, B., and Sacks, D. (2003). Trial 
design and reporting standards for 
intraarterial cerebral thrombolysis for 
acute ischemic stroke. J. Vasc. Interv. 
Radiol. 14(Pt 2), S493–S494.
IMS Study Investigators. (2004). 
Combined intravenous and intra-
arterial recanalization for acute 
ischemic stroke: the interventional 
management of stroke study. Stroke 
35, 904–911.
IMS II Trial Investigators. (2007). The 
interventional management of stroke 
(IMS) II study. Stroke 38, 2127–2135.
Josephson, S. A., Saver, J. L., and Smith, W. 
S. (2009). Comparison of mechanical 
embolectomy and intraarterial throm-
bolysis in acute ischemic stroke within 
the MCA: MERCI and multi MERCI 
compared to PROACT II. Neurocrit. 
Care 10, 43–49.
Katzan, I. L., Hammer, M. D., Hixson, E. 
D., Furlan, A. J., Abou-Chebl, A., and 
Nadzam, D. M. (2004). Utilization of 
intravenous tissue plasminogen acti-
vator for acute ischemic stroke. Arch. 
Neurol. 61, 346–350.
Keris, V., Rudnicka, S., Vorona, V., Enina, 
G., Tilgale, B., and Fricbergs, J. (2001). 
Combined intraarterial/intravenous 
thrombolysis for acute ischemic 
stroke. AJNR Am. J. Neuroradiol. 22, 
352–358.
Khatri, P., Hill, M. D., Palesch, Y. Y., Spilker, 
J., Jauch, E. C., Carrozzella, J. A., 
Demchuk, A. M., Martin, R., Mauldin, 
P., Dillon, C., Ryckborst, K. J., Janis, 
S., Tomsick, T. A., and Broderick, J. P. 
(2008). Methodology of the interven-
tional management of stroke III trial. 
Int. J. Stroke 3, 130–137.
Lee, K. Y., Kim, D. I., Kim, S. H., Lee, S. 
I., Chung, H. W., Shim, Y. W., Kim, S. 
M., and Heo, J. H. (2004). Sequential 
combination of intravenous recom-
binant tissue plasminogen activa-
tor and intra-arterial urokinase in 
acute ischemic stroke. AJNR Am. J. 
Neuroradiol. 25, 1470–1475.
Lee, M., Hong, K. S., and Saver, J. L. (2010). 
Efficacy of intra-arterial fibrinolysis 
for acute ischemic stroke: meta-anal-
ysis of randomized controlled trials. 
Stroke 41, 932–937.
Lees, K. R., Zivin, J. A., Ashwood, T., 
Davalos, A., Davis, S. M., Diener, H. 
C., Grotta, J., Lyden, P., Shuaib, A., 
Hardemark, H. G., Wasiewski, W. W. 
(2006). NXY-059 for acute ischemic 
stroke. N. Engl. J. Med. 354, 588–600.
Frontiers in Neurology | Endovascular and Interventional Neurology  February 2011 | Volume 2 | Article 7 | 8
Knauer and Huber Bridging fibrinolysis in ischemic stroke
removal. Front. Neur. 2:7. doi: 10.3389/
fneur.2011.00007
This article was submitted to Frontiers in 
Endovascular and Interventional Neurology, 
a specialty of Frontiers in Neurology.
Copyright © 2011 Knauer and Huber. 
This is an open-access article subject to an 
exclusive license agreement between the 
authors and Frontiers Media SA, which 
permits unrestricted use, distribution, and 
reproduction in any medium, provided the 
original authors and source are credited.
Conflict of Interest Statement: The 
authors declare that the research was con-
ducted in the absence of any commercial or 
financial relationships that could be con-
strued as a potential conflict of interest.
Received: 06 September 2010; accepted: 
02 February 2011; published online: 22 
February 2011.
Citation: Knauer K and Huber R (2011) 
Fibrinolysis and beyond: bridging the 
gap between local and systemic clot 
Shinohara, Y. (2006). Alteplase at 0.6 
mg/kg for acute ischemic stroke within 
3 hours of onset: Japan alteplase clinical 
trial (J-ACT). Stroke 37, 1810–1815.
Zaidat, O. O., Suarez, J. I., Santillan, C., 
Sunshine, J. L., Tarr, R.W., Paras, V. H., 
Selman, W. R., and Landis, D. M. (2002). 
Response to intra-arterial and combined 
intravenous and intra-arterial throm-
bolytic therapy in patients with distal 
internal carotid artery occlusion. Stroke 
33, 1821–1826.
for acute ischaemic stroke. Cochrane 
Database Syst. Rev. 3, CD000213.
Wolpert, S. M, Bruckmann, H., Greenlee, 
R., Wechsler, L., Pessin, M. S., and del 
Zoppo, G. J. (1993). Neuroradiologic 
evaluation of patients with acute 
stroke treated with recombinant tis-
sue plasminogen activator. The rt-PA 
acute stroke study group. AJNR Am. J. 
Neuroradiol. 14, 3–13.
Yamaguchi, T., Mori, E., Minematsu, K., 
Nakagawara, J., Hashi, K., Saito, I., and 
